Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

[Cardionephrology: past, present and future].

Timio M, Wizemann V.

G Ital Nefrol. 2014 Sep-Oct;31(5). pii: gin/31.5.12. Italian.

2.

Significance of interdialytic weight gain versus chronic volume overload: consensus opinion.

Hecking M, Karaboyas A, Antlanger M, Saran R, Wizemann V, Chazot C, Rayner H, Hörl WH, Pisoni RL, Robinson BM, Sunder-Plassmann G, Moissl U, Kotanko P, Levin NW, Säemann MD, Kalantar-Zadeh K, Port FK, Wabel P.

Am J Nephrol. 2013;38(1):78-90. doi: 10.1159/000353104. Epub 2013 Jul 6.

3.

Treatment frequency and efficiency in hemodiafiltration.

Beck W, Techert F, Lebsanft H, Haug U, Deppisch R, Ledebo I, Wizemann V.

Blood Purif. 2013;35(1-3):224-9. doi: 10.1159/000348444. Epub 2013 Apr 27.

PMID:
23635838
4.

Acetate-free biofiltration reduces intradialytic hypotension: a European multicenter randomized controlled trial.

Tessitore N, Santoro A, Panzetta GO, Wizemann V, Perez-Garcia R, Martinez Ara J, Perrone B, Mantovani W, Poli A.

Blood Purif. 2012;34(3-4):354-63. doi: 10.1159/000346293. Epub 2013 Feb 12.

5.

Geographical variability of patient characteristics and treatment patterns affect outcomes for incident hemodialysis patients.

Martin-Malo A, Papadimitriou M, Cruz J, Bustamante J, Verbeelen D, Nony A, Vanholder R, Jacobson SH, Montenegro J, Hannedouche T, Wizemann V, Locatelli F; Membrane Permeability Outcome (MPO) Study Group.

J Nephrol. 2013 Jan-Feb;26(1):119-28. doi: 10.5301/jn.5000116.

PMID:
22476964
6.

Importance of normohydration for the long-term survival of haemodialysis patients.

Chazot C, Wabel P, Chamney P, Moissl U, Wieskotten S, Wizemann V.

Nephrol Dial Transplant. 2012 Jun;27(6):2404-10. doi: 10.1093/ndt/gfr678. Epub 2012 Jan 17.

PMID:
22253067
7.

Epoetin bubble: a severe German case Honi soit qui mal y pense.

Wizemann V.

Nephrol Dial Transplant. 2011 May;26(5):1750-2; author reply 1752. doi: 10.1093/ndt/gfr016. Epub 2011 Mar 4. No abstract available.

PMID:
21378149
8.

Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.

Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A; Epoetin Zeta Study Group.

Adv Ther. 2010 Feb;27(2):105-17. doi: 10.1007/s12325-010-0012-y. Epub 2010 Mar 30.

PMID:
20369312
9.

Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study.

Fliser D, Kleophas W, Dellanna F, Winkler RE, Backs W, Kraatz U, Fassbinder W, Wizemann V, Strack G.

Curr Med Res Opin. 2010 May;26(5):1083-9. doi: 10.1185/03007991003666652. Erratum in: Curr Med Res Opin. 2010 Aug;26(8):1826. Dellana, F [corrected to Dellanna, F].

PMID:
20225992
10.

Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy.

Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM.

Kidney Int. 2010 Jun;77(12):1098-106. doi: 10.1038/ki.2009.477. Epub 2010 Jan 6.

11.

The mortality risk of overhydration in haemodialysis patients.

Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, Malecka-Masalska T, Marcelli D.

Nephrol Dial Transplant. 2009 May;24(5):1574-9. doi: 10.1093/ndt/gfn707. Epub 2009 Jan 7.

12.

Effect of membrane permeability on survival of hemodialysis patients.

Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R; Membrane Permeability Outcome (MPO) Study Group.

J Am Soc Nephrol. 2009 Mar;20(3):645-54. doi: 10.1681/ASN.2008060590. Epub 2008 Dec 17.

13.

Towards improved cardiovascular management: the necessity of combining blood pressure and fluid overload.

Wabel P, Moissl U, Chamney P, Jirka T, Machek P, Ponce P, Taborsky P, Tetta C, Velasco N, Vlasak J, Zaluska W, Wizemann V.

Nephrol Dial Transplant. 2008 Sep;23(9):2965-71. doi: 10.1093/ndt/gfn228. Epub 2008 May 5.

PMID:
18458032
14.

Whole-body spectroscopy (BCM) in the assessment of normovolemia in hemodialysis patients.

Wizemann V, Rode C, Wabel P.

Contrib Nephrol. 2008;161:115-118. doi: 10.1159/000130423.

PMID:
18451666
15.

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group.

Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264. Erratum in: Curr Med Res Opin. 2008 Apr;24(4):1155. Curr Med Res Opin. 2008 Oct;24(10):3007.

PMID:
18208642
16.

The MPO Study: just a European HEMO Study or something very different?

Locatelli F, Gauly A, Czekalski S, Hannedouche T, Jacobson SH, Loureiro A, Martin-Malo A, Papadimitriou M, Passlick-Deetjen J, Ronco C, Vanholder R, Wizemann V; Membrane Permeability Outcome (MPO) Study Group.

Blood Purif. 2008;26(1):100-4. doi: 10.1159/000110574. Epub 2008 Jan 10. Review.

PMID:
18182806
17.

High blood flow rates with adjustment of needle diameter do not increase hemolysis during hemodialysis treatment.

Techert F, Techert S, Woo L, Beck W, Lebsanft H, Wizemann V.

J Vasc Access. 2007 Oct-Dec;8(4):252-7.

PMID:
18161670
18.

Low- (classical) and high-efficiency haemodiafiltration.

Wizemann V.

Contrib Nephrol. 2007;158:103-109. doi: 10.1159/000107240. Review.

PMID:
17684348
19.

Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS).

Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba T, Kurokawa K, Ramirez S, Young EW.

Am J Kidney Dis. 2007 Mar;49(3):426-31.

PMID:
17336704
20.

Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS.

Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK.

Kidney Int. 2006 Apr;69(7):1222-8.

21.

Detection limit of methods to assess fluid status changes in dialysis patients.

Kraemer M, Rode C, Wizemann V.

Kidney Int. 2006 May;69(9):1609-20.

22.

Si tacuisses...

Wizemann V.

Am J Kidney Dis. 2005 Oct;46(4):787; author reply 788-9. No abstract available.

PMID:
16183438
23.

Thoracic impedance measurements during orthostatic change test and during hemodialysis in hemodialyzed patients.

Swatowski A, Wizemann V, Załuska W, Ksizek A.

ASAIO J. 2004 Nov-Dec;50(6):581-5.

PMID:
15672792
24.

Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients.

Andreucci VE, Fissell RB, Bragg-Gresham JL, Ethier J, Greenwood R, Pauly M, Wizemann V, Port FK.

Am J Kidney Dis. 2004 Nov;44(5 Suppl 2):61-7.

PMID:
15486876
26.

A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedance.

Chamney PW, Krämer M, Rode C, Kleinekofort W, Wizemann V.

Kidney Int. 2002 Jun;61(6):2250-8.

27.

Extracorporeal pressure monitoring and the detection of vascular access stenosis.

Kleinekofort W, Kraemer M, Rode C, Wizemann V.

Int J Artif Organs. 2002 Jan;25(1):45-50.

PMID:
11853071
28.

Cellular interleukin-1 receptor antagonist production in patients receiving on-line haemodiafiltration therapy.

Canaud B, Wizemann V, Pizzarelli F, Greenwood R, Schultze G, Weber C, Falkenhagen D.

Nephrol Dial Transplant. 2001 Nov;16(11):2181-7.

PMID:
11682665
29.

Efficacy of haemodiafiltration.

Wizemann V, Külz M, Techert F, Nederlof B.

Nephrol Dial Transplant. 2001;16 Suppl 4:27-30. Review. No abstract available.

PMID:
11402094
30.

Regular dialysis treatment in Germany: the role of non-profit organisations.

Wizemann V.

J Nephrol. 2000 Nov-Dec;13 Suppl 3:S16-9.

PMID:
11132028
31.

On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study.

Wizemann V, Lotz C, Techert F, Uthoff S.

Nephrol Dial Transplant. 2000;15 Suppl 1:43-8.

PMID:
10737166
32.

A prospective randomised European multicentre study of medium-long run mortality and morbidity comparing acetate-free biofiltration and bicarbonate dialysis.

Santoro A, Panzetta G, Tessitore N, Atti M, Mancini E, Esteban J, London G, Ara JM, Miguel JL, Neumann KH, Opatrny K, Perez R, Perrone B, Wizemann V, Zucchelli P.

J Nephrol. 1999 Nov-Dec;12(6):375-82.

PMID:
10626827
33.

Dynamic pressure measurement for detection of blood access stenosis.

Polaschegg HD, Techert F, Wizemann V.

EDTNA ERCA J. 1998 Oct-Dec;24(4):39-44.

PMID:
10222916
34.

Coronary artery disease in dialysis patients.

Wizemann V.

Contrib Nephrol. 1998;124:1-9; discussion 9-17. Review. No abstract available.

PMID:
9761973
35.

Dialysis schedule-related fluid state and cardiovascular effects.

Wizemann V, Timio M.

Nephrol Dial Transplant. 1998;13 Suppl 6:91-3. Review. No abstract available.

PMID:
9719212
36.

[Coronary risk factors in chronic hemodialysis patients].

Lübbecke F, Matthias FR, Richter U, Frettlöh A, Katz N, Wizemann V, Schütterle G.

Med Klin (Munich). 1996 Nov 15;91(11):687-93. German.

PMID:
9036291
37.

Points to remember when dialysing the patient with coronary disease.

Wizemann V.

Nephrol Dial Transplant. 1996 Feb;11(2):236-8. No abstract available.

PMID:
8671771
38.

Coronary artery disease in dialysis patients.

Wizemann V.

Nephron. 1996;74(4):642-51.

PMID:
8956296
39.

Dilemma of assessing volume state--the use and the limitations of a clinical score.

Wizemann V, Schilling M.

Nephrol Dial Transplant. 1995 Nov;10(11):2114-7. No abstract available.

PMID:
8643179
40.

Influence of hydration state on plasma volume changes during ultrafiltration.

Wizemann V, Leibinger A, Mueller K, Nilson A.

Artif Organs. 1995 May;19(5):416-9.

PMID:
7625920
41.

Protein adsorption by artificial membrane materials under filtration conditions.

Birk HW, Kistner A, Wizemann V, Schütterle G.

Artif Organs. 1995 May;19(5):411-5.

PMID:
7625919
42.

Hemodialysis and the heart.

Alpert MA, Wizemann V, Nolph KD, Van Stone J, Culpepper MC.

Am J Med Sci. 1995 Feb;309(2):110-21. Review. No abstract available.

PMID:
7847441
43.

A dialysis patient with fatigue and ascites.

Wizemann V, Kramer W.

Nephrol Dial Transplant. 1995;10(9):1778-9. No abstract available.

PMID:
8559508
44.

Hemodialysis: 70 years.

Wizemann V.

Clin Investig. 1994 Sep;72(9):720-1. No abstract available.

PMID:
7849459
45.

Noninvasive assessment of left ventricular structure and function in patients with end-stage renal disease.

Alpert MA, Wizemann V, Hüting J, Massey CV.

Contrib Nephrol. 1994;106:13-25. Review. No abstract available.

PMID:
8174358
46.

Importance of arterial hypertension for left ventricular hypertrophy in patients after kidney transplantation.

Hüting J, Naumann-Hüting C, Wizemann V.

Contrib Nephrol. 1994;106:119-24. No abstract available.

PMID:
8174355
47.

Diastolic dysfunction of the left ventricle in dialysis patients.

Wizemann V, Blank S, Kramer W.

Contrib Nephrol. 1994;106:106-9. Review. No abstract available.

PMID:
8174352
48.

Thrombocyte alpha-2-adrenoceptors and hypotension in hemodialyzed patients.

Lübbecke F, Wizemann V, Schütterle G.

Nephron. 1994;68(2):268-9. No abstract available.

49.

Nephrology dialysis transplantation 70th anniversary of haemodialysis--the pioneering contribution of Georg Haas (1886-1971).

Wizemann V, Benedum J.

Nephrol Dial Transplant. 1994;9(12):1829-31. No abstract available.

PMID:
7708277
50.

Options in dialysis therapy: significance of cardiovascular findings.

Wizemann V, Timio M, Alpert MA, Kramer W.

Kidney Int Suppl. 1993 Feb;40:S85-91. Review.

PMID:
8445844

Supplemental Content

Loading ...
Support Center